Effects of rilonacept injection: A Synthesis of Findings from 24 Studies

  1. Home
  2. Effects of rilonacept injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of rilonacept injection: A Synthesis of Findings from 24 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of rilonacept injection: A Synthesis of Findings from 24 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Rilonacept is a medication that blocks the activity of interleukin-1 (IL-1), which is a protein that is involved in inflammation. It has been studied for use in treating various inflammatory conditions. 17 , 4 , 13 , 9 , 18 , 7 , 14 , 11 , 20 , 22 . Multiple studies have shown that rilonacept is effective in treating conditions such as cryopyrin-associated periodic syndromes (CAPS), recurrent pericarditis, gout attacks, and familial Mediterranean fever (FMF). 13 , 7 , 14 , 9 , 18 . Rilonacept also shows potential in reducing cardiac remodeling after heart attacks. 21 . Rilonacept has generally been shown to be safe and well-tolerated. 13 , 7 , 14 , 9 , 18 . However, some side effects, such as injection site reactions, have been reported. 10 .

Benefits and Risks

Benefits Summary

Rilonacept has been shown to be effective in treating conditions such as CAPS, recurrent pericarditis, gout attacks, and FMF. 13 , 7 , 14 , 9 , 18 . Rilonacept also shows potential in reducing cardiac remodeling after heart attacks. 21 . Rilonacept has generally been shown to be safe and well-tolerated. 13 , 7 , 14 , 9 , 18 .

Risk Summary

A common side effect of rilonacept is injection site reactions. 10 .

Comparison Across Studies

Commonalities in Studies

Multiple studies have shown that rilonacept is effective in treating various inflammatory conditions. 13 , 7 , 14 , 9 , 18 . Also, rilonacept has generally been shown to be safe and well-tolerated. 13 , 7 , 14 , 9 , 18 .

Differences in Studies

The types of inflammatory conditions that rilonacept has been shown to be effective in treating, and the frequency of side effects, vary between studies. 13 , 7 , 14 , 9 , 18 . Therefore, it is important to follow your doctor's instructions regarding the use of rilonacept.

Consistency and Contradictions of Results

Multiple studies have shown consistent results indicating that rilonacept is effective in treating various inflammatory conditions. 13 , 7 , 14 , 9 , 18 . However, the types of inflammatory conditions that rilonacept has been shown to be effective in treating, and the frequency of side effects, vary between studies, suggesting that further research is needed. 13 , 7 , 14 , 9 , 18 .

Implications for Everyday Life

It is important to follow your doctor's instructions when taking rilonacept. 13 , 7 , 14 , 9 , 18 . Rilonacept is not effective in treating all inflammatory conditions. There are also risks of side effects. 13 , 7 , 14 , 9 , 18 . Therefore, it is crucial to consult with your doctor before taking rilonacept.

Limitations of Current Research

Further research is needed to fully understand the long-term safety and effectiveness of rilonacept. 13 , 7 , 14 , 9 , 18 . Additionally, further research is needed to better understand how rilonacept works. 13 , 7 , 14 , 9 , 18 .

Future Research Directions

Further research is needed to examine the long-term safety and effectiveness of rilonacept, to understand the mechanisms by which it works, and to investigate its effects on various inflammatory conditions. 13 , 7 , 14 , 9 , 18 .

Conclusion

Rilonacept is a medication used to treat various inflammatory conditions. 13 , 7 , 14 , 9 , 18 . Rilonacept has generally been shown to be safe and well-tolerated. 13 , 7 , 14 , 9 , 18 . However, there are risks of side effects. 13 , 7 , 14 , 9 , 18 . It is important to consult with your doctor before taking rilonacept.

Keywords
Benefit Keywords
Pain reduction
1
Improved clinical response
Reduced inflammation
Reduced pain
Reduced recurrence risk
Weaning from background therapy
2
CAPS treatment
4
Human therapy
5
Familial Mediterranean fever treatment
6
Pericarditis treatment
7
Diabetes treatment
8
Reduced gout flares
9
Reduces inflammation
Safe and effective
Treats pericarditis
10
Reduced pericarditis recurrence
11
ESRD rilonacept safety
12
Improved CAPS symptoms
Improved daily activities
Improved disease activity
Normalized SAA levels
Reduced CAPS flare days
13
Improved RP treatment
Reduced IL-1 signaling
14
Amyloidosis prevention
FMF attack prevention
Improved compliance
Reduced drug-drug interactions
Reduced gastrointestinal side effects
15
Familial Mediterranean fever treatment
16
IL-1beta inhibition
17
Reduced attack frequency
18
Improved JIA
19
Reduced pericarditis recurrence
20
Cardiac remodeling reduction
21
Improved CAPS symptoms
Normalized inflammation
22
Achieved remission
Maintained function
Relieved pain
Suppressed inflammation
24
Risk Keywords
Injection site reaction
1
Injection site reactions
Upper respiratory tract infections
2
Cutaneous events
Hematologic events
Hypersensitivity
Immunogenicity
Renal events
Respiratory events
5
Colchicine intolerance
Colchicine resistance
6
Rilonacept side effects
7
Injection site reactions
9
Injection site reactions
10
Injection-site reactions
Upper respiratory tract infections
11
Injection site reactions
13
Amyloidosis prevention
Pregnancy safety
15
Injection site reactions
Limited sample size
18
Infections
Injection site reactions
19
Injection site reactions
Upper respiratory infections
22
Toxicity
24
Literature analysis of 24 papers
Positive Content
23
Neutral Content
1
Negative Content
0
Article Type
4
2
3
9
23
1.

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.

Author: TerkeltaubR, SundyJ S, SchumacherH R, MurphyF, BookbinderS, BiedermannS, WuR, MellisS, RadinA

Pain reduction
Injection site reaction

Rilonacept is a new drug that may help reduce pain in patients with chronic gouty arthritis. In a study of 10 patients, rilonacept was well tolerated and showed significant improvement in pain scores. However, larger, randomized studies are needed to confirm these findings.

Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

3.

Interventions for reducing inflammation in familial Mediterranean fever.

Author: YinXi, TianFangyuan, WuBin, XuTing

This is an updated review of the treatment options for Familial Mediterranean fever (FMF), a hereditary autoinflammatory disease, including colchicine, anakinra, rilonacept, canakinumab, etanercept, infliximab, and adalimumab.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

4.

Rilonacept in the treatment of chronic inflammatory disorders.

Author: McDermottMichael F

CAPS treatment

This study discusses rilonacept, a long-acting interleukin-1 (IL-1) blocker, for the treatment of two cryopyrin-associated periodic syndromes (CAPS) disorders, FCAS and MWS. Rilonacept offers a potential alternative to patients who cannot tolerate daily injections or have difficulty with drug compliance.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Author: BaldoBrian A

Human therapy
Cutaneous events
Hematologic events
Hypersensitivity
Immunogenicity
Renal events
Respiratory events

This review covers eight fusion proteins that have received regulatory approval for human therapy: etanercept, belatacept, abatacept, alefacept, rilonacept, romiplostim, aflibercept, and denileukin-diftitox.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Interventions for reducing inflammation in familial Mediterranean fever.

Author: WuBin, XuTing, LiYouping, YinXi

Familial Mediterranean fever treatment
Colchicine intolerance
Colchicine resistance

Familial Mediterranean fever (FMF) is an auto-inflammatory disease. Colchicine is an effective treatment, but for those who are resistant or intolerant, alternative medications like rilonacept, anakinra, etanercept, infliximab, thalidomide, and interferon-alpha may provide benefits.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

7.

New Indication for Rilonacept.

Author: AschenbrennerDiane S

Pericarditis treatment
Rilonacept side effects

Rilonacept is a subcutaneous medication approved to treat recurrent pericarditis in adults and children 12 years and older.

NewsMedia reports that provide information on the latest events and information. Newspapers, television, and the Internet are the main media.

Language : English

8.

Administration of IL-1 trap prolongs survival of transplanted pancreatic islets to type 1 diabetic NOD mice.

Author: RydgrenTobias, ÖsterElin, SandbergMonica, SandlerStellan

Diabetes treatment

This study investigated the effect of IL-1 Trap, a hybrid molecule that blocks IL-1β, on the recurrence of disease in a mouse model of type 1 diabetes. IL-1 Trap administration significantly increased graft survival in some mice, suggesting a potential therapeutic benefit in preventing islet cell destruction.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.

Author: SundyJohn S, SchumacherH Ralph, KivitzAlan, WeinsteinSteven P, WuRichard, King-DavisShirletta, EvansRobert R

Reduced gout flares
Injection site reactions

Rilonacept 160 mg once weekly was safe and significantly reduced the risk of gout flares in patients initiating or continuing urate-lowering therapy.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Anti-interleukin-1 agents for pericarditis: a primer for cardiologists.

Author: ImazioMassimo, LazarosGeorge, GattornoMarco, LeWinterMartin, AbbateAntonio, BrucatoAntonio, KleinAllan

Reduces inflammation
Safe and effective
Treats pericarditis
Injection site reactions

Anti-interleukin (IL)-1 agents, including anakinra, rilonacept, and canakinumab, have emerged as effective treatments for recurrent idiopathic pericarditis. This article provides a comprehensive review of these agents, highlighting their efficacy and safety in treating corticosteroid-dependent and colchicine-resistant recurrent pericarditis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.

Author: KleinAllan L, ImazioMassimo, CremerPaul, BrucatoAntonio, AbbateAntonio, FangFang, InsalacoAntonella, LeWinterMartin, LewisBasil S, LinDavid, LuisSushil A, NichollsStephen J, PanoArian, WheelerAlistair, PaoliniJohn F,

Reduced pericarditis recurrence
Injection-site reactions
Upper respiratory tract infections

This phase 3 trial evaluated the efficacy and safety of rilonacept in patients with recurrent pericarditis. The study found that rilonacept led to rapid resolution of recurrent pericarditis episodes and to a significantly lower risk of pericarditis recurrence than placebo.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD).

Author: RadinAllen, MarburyThomas, OsgoodGreg, BelomestnovPavel

ESRD rilonacept safety

A single dose of rilonacept, an IL-1 inhibitor, was found to be safe and effective in patients with end-stage renal disease (ESRD), with no dose adjustment necessary.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Author: HoffmanHal M, ThroneMartin L, AmarN J, SebaiMohamed, KivitzAlan J, KavanaughArthur, WeinsteinSteven P, BelomestnovPavel, YancopoulosGeorge D, StahlNeil, MellisScott J

Improved CAPS symptoms
Improved daily activities
Improved disease activity
Normalized SAA levels
Reduced CAPS flare days
Injection site reactions

Weekly rilonacept, an IL-1 inhibitor, significantly improved clinical signs and symptoms of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), with a favorable safety profile.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Rilonacept for the treatment of recurrent pericarditis.

Author: FavaAgostina M, ReyaldeenReza, Lo PrestiSaberio, GoyalAmit, AkintoyeEmmanuel, HughesDiarmaid, KleinAllan L

Improved RP treatment
Reduced IL-1 signaling

Rilonacept, an IL-1 inhibitor, is a promising therapeutic option for recurrent pericarditis due to its effectiveness in blocking IL-1 signaling. This suggests that rilonacept could be a valuable treatment for this debilitating disease.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

15.

IL-1 inhibition in familial Mediterranean fever: clinical outcomes and expectations.

Author: KharoufFadi, Tsemach-TorenTehila, Ben-ChetritEldad

Amyloidosis prevention
FMF attack prevention
Improved compliance
Reduced drug-drug interactions
Reduced gastrointestinal side effects
Amyloidosis prevention
Pregnancy safety

This review discusses the limitations of colchicine therapy for familial Mediterranean fever (FMF) and the potential benefits of anti-interleukin-1 (anti-IL-1) agents.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Interventions for reducing inflammation in familial Mediterranean fever.

Author: WuBin, XuTing, LiYouping, YinXi

Familial Mediterranean fever treatment

Colchicine is the primary treatment for familial Mediterranean fever, but other medications, including rilonacept, anakinra, and canakinumab, can be beneficial for those who are colchicine-resistant or intolerant.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

17.

A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.

Author: Goldbach-ManskyRaphaela, ShroffSharukh D, WilsonMildred, SnyderChristopher, PlehnSara, BarhamBeverly, PhamTuyet-Hang, PucinoFrank, WesleyRobert A, PapadopoulosJoanne H, WeinsteinSteven P, MellisScott J, KastnerDaniel L

IL-1beta inhibition

This pilot study investigated the safety and efficacy of rilonacept (IL-1 Trap) in patients with familial cold autoinflammatory syndrome (FCAS), a condition caused by excessive interleukin-1beta (IL-1beta) secretion. The study aimed to assess the safety and potential benefits of rilonacept, a long-acting IL-1 receptor fusion protein, in treating FCAS.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.

Author: HashkesPhilip J, SpaldingSteven J, GianniniEdward H, HuangBin, JohnsonAnne, ParkGrace, BarronKaryl S, WeismanMichael H, PashinianNoune, ReiffAndreas O, SamuelsJonathan, WrightDowain A, KastnerDaniel L, LovellDaniel J

Reduced attack frequency
Injection site reactions
Limited sample size

Rilonacept, an interleukin-1 decoy receptor, significantly reduces the frequency of familial Mediterranean fever (FMF) attacks in patients who are resistant to or intolerant of colchicine. The median number of attacks per month was significantly lower with rilonacept compared to placebo. However, the duration of attacks was not significantly different between the two treatment groups. The most common side effect was injection site reactions, which were more frequent with rilonacept.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

19.

Biologics in children's autoimmune disorders: efficacy and safety.

Author: BredaLuciana, Del TortoMarianna, De SanctisSara, ChiarelliFrancesco

Improved JIA
Infections
Injection site reactions

Biologic drugs are a type of medication that targets specific parts of the immune system. They are used to treat a variety of autoimmune diseases, including juvenile idiopathic arthritis (JIA). This review discussed the current state of biologic drugs for treating JIA.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

20.

RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis.

Author: KleinAllan L, ImazioMassimo, BrucatoAntonio, CremerPaul, LeWinterMartin, AbbateAntonio, LinDavid, MartiniAlberto, BeutlerAnna, ChangSteven, FangFang, GervaisAnais, PerrinRandy, PaoliniJohn F

Reduced pericarditis recurrence

This study, RHAPSODY, is a Phase 3 trial evaluating the efficacy and safety of rilonacept, an interleukin-1 inhibitor, in the treatment of recurrent pericarditis (RP). The trial aims to improve outcomes and quality of life for patients with RP.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

21.

Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice.

Author: Van TassellBenjamin W, VarmaAmit, SalloumFadi N, DasAnindita, SeropianIgnacio M, ToldoStefano, SmithsonLisa, HokeNicholas N, ChauVinh Q, RobatiRoshanak, AbbateAntonio

Cardiac remodeling reduction

IL-1 Trap, a protein that binds IL-1, was studied for its potential to reduce cardiac remodeling after a heart attack in mice. The study's results will be used to determine the effectiveness of IL-1 Trap in humans.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

22.

Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.

Author: HoffmanHal M, ThroneMartin L, AmarNiran J, CartwrightRobert C, KivitzAlan J, SooYuhwen, WeinsteinSteven P

Improved CAPS symptoms
Normalized inflammation
Injection site reactions
Upper respiratory infections

Long-term treatment with rilonacept, an interleukin-1 inhibitor, for up to 96 weeks resulted in significant improvements in clinical signs and symptoms of Cryopyrin-associated periodic syndromes (CAPS). The treatment also normalized inflammatory biomarkers and exhibited a favorable safety profile in both adults and children.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

23.

Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis.

Author: TorresR, MacdonaldL, CrollS D, ReinhardtJ, DoreA, StevensS, HyltonD M, RudgeJ S, Liu-BryanR, TerkeltaubR A, YancopoulosG D, MurphyA J

This study investigates the role of interleukin 1 beta (IL1beta) in crystal-induced inflammation. IL1beta release is known to contribute to inflammation in models of acute gout and pseudogout, but the consequences of IL1 inhibition have not been fully explored.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.